<DOC>
	<DOCNO>NCT00976768</DOCNO>
	<brief_summary>The purpose study : - To observe feasibility biweekly oxaliplatin infusional 5-fluorouracil ( FU ) /Leucovorin ( LV ) patient advance gastric adenocarcinoma prior exposure taxane , fluoropyrimidine , cisplatin - To determine activity combination regimen . - To evaluate treatment-related toxicity .</brief_summary>
	<brief_title>Biweekly FOLFIRI Advanced Gastric Cancer ( AGC ) With Failure Prior Taxane , Fluoropyrimidine , Cisplatin</brief_title>
	<detailed_description>There presently chemotherapy regimen consider standard care patient advance gastric cancer . However , patient receive fluoropyrimidine , platinum , taxane combination sequential chemotherapy . Unfortunately , half patient receive chemotherapy unresponsive treatment result salvage chemotherapy unsatisfactory . For patient , currently establish palliative chemotherapy option , urgent need novel , active , less toxic regimen patient advance gastric cancer fail front-line chemotherapy . On base , investigate activity biweekly oxaliplatin 5-FU/LV patient advance gastric cancer fail prior taxane , fluoropyrimidine cisplatin chemotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Pathologically proven nonresectable adenocarcinoma stomach Measurable disease base Response Criteria Solid Tumors ( RECIST ) Prior chemotherapy taxane , fluoropyrimidine , cisplatinum combination sequentially , time limit last chemotherapy Age 18 70 year old Estimated life expectancy 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 2 low Adequate bone marrow function ( white blood cell count &gt; 4,000/µL , absolute neutrophil count [ ANC ] &gt; 1,500/µL , hemoglobin &gt; 9.0 g/dL , platelet &gt; 100,000/µL ) , Adequate kidney function ( creatinine &lt; 1.5 mg/dL ) Adequate liver function ( bilirubin &lt; 1.5 mg/dL , transaminases level &lt; 3 time upper normal limit [ 5 time patient liver metastasis ] , serum albumin &gt; 2.5 mg/dL ) Other tumor type adenocarcinoma Presence history central nervous system metastasis Obvious impend bowel obstruction ( include obvious peritoneal carcinomatosis ) Evidence active gastrointestinal bleeding Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>